Aerpio’s AKB-9778 as adjunct reduces IOP in phase 1b trial

A topical ocular formulation of AKB-9778 given as an adjunctive therapy reduced IOP and was well tolerated in patients with ocular hypertension or primary open-angle glaucoma, according to a press release from Aerpio Pharmaceuticals.
Building on previous results of favorable tolerability and pharmacodynamic findings in ocular normotensive subjects, Aerpio recruited a cohort with OHT/POAG to assess the safety, tolerability and efficacy of once-daily AKB-9778, a Tie2-activating compound, as an adjunctive therapy to prostaglandin.
The phase 1b study consisted of 43 patients with IOP between 17 mm

Full Story →